RefleXion Welcomes Two New Management Team Members

RefleXion Medical has appointed Steve Schoch as chief financial officer (CFO) and promoted Phil Aulson to chief operating officer (COO). Both report to President/CEO Todd Powell.

“Steve’s 30-year track record of excellence and diverse background will be a tremendous asset to the RefleXion team,” Powell said. “He brings extensive experience in fundraising, financial infrastructure and operations management—critical components that will help RefleXion transition from an early-stage to a growth-stage commercial company.”

Before joining RefleXion, Schoch was COO and CFO at travel technology company FLYR Inc., where he restructured its global business and financial operations. Previously, he was CFO at 23andMe and led a nearly $1 billion equity raise, including the company’s 2021 initial public offering. His executive tenure also includes roles at Miramax and Amgen. He currently serves as a board member and audit committee chair of clinical-stage biotechnology firm Zura Bio Ltd.

Aulson joined RefleXion in 2016 as director of new product introduction. His more than 25 years of experience in medical device manufacturing includes leadership roles at Fortune 500 and startup companies. Before joining RefleXion, he held executive and senior management positions at Oraya Therapeutics, Insound Medical, Hansen Medical, Boston Scientific Corp., and Depuy/Johnson & Johnson.

“Phil has been instrumental in developing our first factory, and establishing our manufacturing, operations, customer service and success teams,” Powell stated. “He is a proven leader who brings a strong focus on operational execution to RefleXion.”

RefleXion Medical develops and commercializes SCINTIX biology-guided radiotherapy, a treatment that uses a single radiotracer injection to transform cancer cells into real-time biological beacons to control external-beam radiotherapy delivery to single or multiple tumors. SCINTIX therapy is indicated for use in FDG-guided treatment of lung and bone tumors and is being studied for broader indications. In addition, the company offers the RefleXion X1 system for conventional radiotherapy for all solid tumors.